143 related articles for article (PubMed ID: 23083945)
1. Psychotomimetic effects of kappa opioid receptor agonists.
White KL; Roth BL
Biol Psychiatry; 2012 Nov; 72(10):797-8. PubMed ID: 23083945
[No Abstract] [Full Text] [Related]
2. Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.
Hasebe K; Kawai K; Suzuki T; Kawamura K; Tanaka T; Narita M; Nagase H; Suzuki T
Ann N Y Acad Sci; 2004 Oct; 1025():404-13. PubMed ID: 15542743
[TBL] [Abstract][Full Text] [Related]
3. N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.
Béguin C; Potter DN; Dinieri JA; Munro TA; Richards MR; Paine TA; Berry L; Zhao Z; Roth BL; Xu W; Liu-Chen LY; Carlezon WA; Cohen BM
J Pharmacol Exp Ther; 2008 Jan; 324(1):188-95. PubMed ID: 17951511
[TBL] [Abstract][Full Text] [Related]
4. Biased agonism at kappa opioid receptors: Implication in pain and mood disorders.
Dogra S; Yadav PN
Eur J Pharmacol; 2015 Sep; 763(Pt B):184-90. PubMed ID: 26164787
[TBL] [Abstract][Full Text] [Related]
5. Kappa opioids as potential treatments for stimulant dependence.
Prisinzano TE; Tidgewell K; Harding WW
AAPS J; 2005 Oct; 7(3):E592-9. PubMed ID: 16353938
[TBL] [Abstract][Full Text] [Related]
6. Cognition: the ultimate brain function.
Robbins TW
Neuropsychopharmacology; 2011 Jan; 36(1):1-2. PubMed ID: 21116247
[No Abstract] [Full Text] [Related]
7. The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?
Shippenberg TS
Neuropsychopharmacology; 2009 Jan; 34(1):247. PubMed ID: 19079072
[No Abstract] [Full Text] [Related]
8. Melatonin MT
Comai S; Lopez-Canul M; De Gregorio D; Posner A; Ettaoussi M; Guarnieri FC; Gobbi G
Pharmacol Res; 2019 Jun; 144():343-356. PubMed ID: 31029764
[TBL] [Abstract][Full Text] [Related]
9. Kappa-opioid ligands in the study and treatment of mood disorders.
Carlezon WA; Béguin C; Knoll AT; Cohen BM
Pharmacol Ther; 2009 Sep; 123(3):334-43. PubMed ID: 19497337
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of κ-opioids for treatment of pain and addiction.
Chavkin C
Neuropsychopharmacology; 2011 Jan; 36(1):369-70. PubMed ID: 21116263
[No Abstract] [Full Text] [Related]
11. Intracellular signalling pathways and mood disorders.
Fišar Z; Hroudová J
Folia Biol (Praha); 2010; 56(4):135-48. PubMed ID: 20974046
[TBL] [Abstract][Full Text] [Related]
12. The role of kappa-opioid receptor activation in mediating antinociception and addiction.
Wang YH; Sun JF; Tao YM; Chi ZQ; Liu JG
Acta Pharmacol Sin; 2010 Sep; 31(9):1065-70. PubMed ID: 20729876
[TBL] [Abstract][Full Text] [Related]
13. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.
Wee S; Koob GF
Psychopharmacology (Berl); 2010 Jun; 210(2):121-35. PubMed ID: 20352414
[TBL] [Abstract][Full Text] [Related]
14. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
[TBL] [Abstract][Full Text] [Related]
15. Psychiatric drugs in medical practice.
Coyle JT
Med Clin North Am; 1977 Jul; 61(4):891-905. PubMed ID: 195166
[No Abstract] [Full Text] [Related]
16. Endocannabinoids and Mental Disorders.
Rubino T; Zamberletti E; Parolaro D
Handb Exp Pharmacol; 2015; 231():261-83. PubMed ID: 26408164
[TBL] [Abstract][Full Text] [Related]
17. The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.
Clark SD; Abi-Dargham A
Biol Psychiatry; 2019 Oct; 86(7):502-511. PubMed ID: 31376930
[TBL] [Abstract][Full Text] [Related]
18. Kappa opioid receptor inhibition of glutamatergic transmission in the nucleus accumbens shell.
Hjelmstad GO; Fields HL
J Neurophysiol; 2001 Mar; 85(3):1153-8. PubMed ID: 11247984
[TBL] [Abstract][Full Text] [Related]
19. Psychotic Decompensation During Nalmefene Treatment in a Patient With Schizoaffective Disorder: A Case Report.
Salles J; Ponté C; Schmitt L
J Dual Diagn; 2019; 15(2):118-121. PubMed ID: 30829564
[No Abstract] [Full Text] [Related]
20. Psychedelics and Personality.
Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
